Sugi Predict

Sugi Predict / Compounds / SCHEMBL5133787

SCHEMBL5133787

SCHEMBL5133787

CC1(C)CCC(C)(C)c2c(NC(=O)c3ccc(CF)cc3)cc(C(=O)C=Cc3ccc(C(=O)O)cc3)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 13/20 0.46
▸ RARG P13631 13/20 0.46
▸ RARA P10276 12/20 0.46
▸ CYP26A1 O43174 6/20 0.43
▸ CYP3A4 P08684 4/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ PGR P06401 1/20 0.43
▸ ADORA3 P0DMS8 1/20 0.43
▸ TBXA2R P21731 1/20 0.43
▸ BLVRB P30043 1/20 0.43
▸ RXRA P19793 4/20 0.40
▸ TP53 P04637 2/20 0.40
▸ BLM P54132 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5133574 0.90 MET (0.48) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5133575 0.90 MET (0.48) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5049689 0.89 RARA (0.47) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5049685 0.89 RARA (0.47) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5133788 0.87 RARB (0.42) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5047124 0.86 RARA (0.45) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5047119 0.86 RARA (0.45) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5132412 0.85 RARB (0.59) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5048417 0.82 RARA (0.46) RARBRARGRARACYP26A1CYP3A4
SCHEMBL5048411 0.82 RARA (0.46) RARBRARGRARACYP26A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 — — US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 — — US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 — — US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARG 3/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.